全文获取类型
收费全文 | 12525篇 |
免费 | 790篇 |
国内免费 | 85篇 |
专业分类
耳鼻咽喉 | 113篇 |
儿科学 | 377篇 |
妇产科学 | 180篇 |
基础医学 | 1503篇 |
口腔科学 | 519篇 |
临床医学 | 1073篇 |
内科学 | 3064篇 |
皮肤病学 | 311篇 |
神经病学 | 1068篇 |
特种医学 | 512篇 |
外科学 | 1990篇 |
综合类 | 41篇 |
一般理论 | 1篇 |
预防医学 | 764篇 |
眼科学 | 125篇 |
药学 | 619篇 |
中国医学 | 28篇 |
肿瘤学 | 1112篇 |
出版年
2024年 | 17篇 |
2023年 | 138篇 |
2022年 | 242篇 |
2021年 | 495篇 |
2020年 | 249篇 |
2019年 | 401篇 |
2018年 | 481篇 |
2017年 | 317篇 |
2016年 | 331篇 |
2015年 | 364篇 |
2014年 | 470篇 |
2013年 | 584篇 |
2012年 | 794篇 |
2011年 | 897篇 |
2010年 | 526篇 |
2009年 | 468篇 |
2008年 | 753篇 |
2007年 | 755篇 |
2006年 | 696篇 |
2005年 | 708篇 |
2004年 | 648篇 |
2003年 | 538篇 |
2002年 | 480篇 |
2001年 | 262篇 |
2000年 | 254篇 |
1999年 | 221篇 |
1998年 | 91篇 |
1997年 | 86篇 |
1996年 | 70篇 |
1995年 | 60篇 |
1994年 | 48篇 |
1993年 | 50篇 |
1992年 | 93篇 |
1991年 | 90篇 |
1990年 | 77篇 |
1989年 | 62篇 |
1988年 | 63篇 |
1987年 | 60篇 |
1986年 | 59篇 |
1985年 | 46篇 |
1984年 | 36篇 |
1983年 | 35篇 |
1982年 | 26篇 |
1980年 | 15篇 |
1979年 | 31篇 |
1977年 | 21篇 |
1975年 | 20篇 |
1974年 | 17篇 |
1973年 | 24篇 |
1968年 | 16篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
961.
Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. 总被引:19,自引:0,他引:19
F Ciardiello R Bianco V Damiano S De Lorenzo S Pepe S De Placido Z Fan J Mendelsohn A R Bianco G Tortora 《Clinical cancer research》1999,5(4):909-916
Epidermal growth factor (EGF)-related proteins such as transforming growth factor alpha (TGF-alpha) control cancer cell growth through autocrine and paracrine pathways. Overexpression of TGF-alpha and/or its receptor (EGFR) has been associated with a more aggressive disease and a poor prognosis. The blockade of EGFR activation has been proposed as a target for anticancer therapy. Monoclonal antibody (MAb) C225 is an anti-EGFR humanized chimeric mouse MAb that is presently in Phase II clinical trials in cancer patients. Previous studies have suggested the potentiation of the antitumor activity of certain cytotoxic drugs, such as cisplatin and doxorubicin, in human cancer cell lines by treatment with anti-EGFR antibodies. We have evaluated in human ovarian, breast, and colon cancer cell lines, which express functional EGFR, the antiproliferative activity of MAb C225 in combination with topotecan, a cytotoxic drug that specifically inhibits topoisomerase I and that has shown antitumor activity in these malignancies. A dose-dependent supraadditive increase of growth inhibition in vitro was observed when cancer cells were treated with topotecan and MAb C225 in a sequential schedule. In this respect, the cooperativity quotient, defined as the ratio between the actual growth inhibition obtained by treatment with topotecan followed by MAb C225 and the sum of the growth inhibition achieved by each agent, ranged from 1.2 to 3, depending on drug concentration and cancer cell line. Treatment with MAb C225 also markedly enhanced apoptotic cell death induced by topotecan. For example, in GEO colon cancer cells, 5 nM topotecan, followed by 0.5 microg/ml MAb C225, induced apoptosis in 45% cells as compared with untreated cells (6%) or to 5 nM topotecan-treated cells (22%). Treatment of mice bearing established human GEO colon cancer xenografts with topotecan or with MAb C225 determined a transient inhibition of tumor growth because GEO tumors resumed the growth rate of untreated tumors at the end of the treatment period. In contrast, an almost complete tumor regression was observed in all mice treated with the two agents in combination. This determined a prolonged life span of the mice that was significantly different as compared with controls (P < 0.001), to MAb C225-treated group (P < 0.001), or to the topotecan-treated group (P < 0.001). All mice of the topotecan plus MAb C225 group were the only animals alive 14 weeks after tumor cell injection. Furthermore, 20% of mice in this group were still alive after 19 weeks. The combined treatment with MAb C225 and topotecan was well tolerated by mice with no signs of acute or delayed toxicity. These results provide a rationale for the evaluation of the anticancer activity of the combination of topoisomerase I inhibitors and anti-EGFR blocking MAbs in clinical trials. 相似文献
962.
Amenta M Dalle Nogare ER Colomba C Prestileo TS Di Lorenzo F Fundaro S Colomba A Ferrieri A 《Journal of chemotherapy (Florence, Italy)》1999,11(5):391-395
In HIV-1 infected patients severe enteritis and chronic diarrhea are often documented as a consequence of multiple opportunistic infections. We analyzed 48 HIV-1 positive patients for the presence of intestinal pathogenic protozoa. Patients with CD4 > or = 200/mm3 showed a higher prevalence of a single pathogenic protozoa than patients with CD4 < or =200/mm3, who showed the presence of multiple protozoal infections. Patients who proved positive for only a single protozoa, Cryptosporidium or Blastocystis, were also positive, by stool culture, for the presence of Proteus mirabilis (3 samples), Citrobacter freundii (3 samples), Escherichia coli (one sample) or Enterobacter cloacae (one sample). Treatment with rifaximin (600 mg, 3 times a day, for 14 days) was efficacious in resolving the clinical symptoms and clearing protozoan infections in HIV-1 infected patients with CD4 > or = 200/mm3, who presented enteric and systemic symptoms due to Criptosporidium or Blastocystis associated with enteropathogenic bacteria. 相似文献
963.
Vitantonio Di Bello M.D. Lorenzo Conte M.D. Maria Grazia Delle Donne M.D. Cristina Giannini M.D. Valentina Barletta M.D. Iacopo Fabiani M.D. Caterina Palagi M.D. Carmela Nardi M.D. Frank Lloyd Dini M.D. Letizia Marconi M.D. Pierluigi Paggiaro M.D. Antonio Palla M.D. Mario Marzilli M.D. 《Echocardiography (Mount Kisco, N.Y.)》2013,30(7):820-828
964.
965.
966.
967.
Abstract: The conformational properties of CP‐1042?55, a peptide corresponding to the hinge region of CP‐10, were investigated using circular dichroism spectroscopy and reverse‐phase high‐performance liquid chromatography (RP‐HPLC). The circular dichroism studies indicated that CP‐1042?55 formed considerable secondary structure in the presence of hydrophobic solution environments including 50% acetonitrile, 50% trifluoroethanol and 200 mm sodium dodecyl sulfate, which comprised a mixture of α‐helix and β‐sheet. The effect of temperature on the conformation of CP‐1042?55 was investigated between 5 and 40°C, with very small changes in the spectra being observed.RP‐HPLC was then used to investigate the effect of temperature on the conformation of CP‐1042?55 in the presence of a hydrophobic surface. Using a C18‐adsorbent, CP‐1042?55 exhibited a conformational transition at 25°C, which was associated with an increase in the chromatographic contact area and the binding affinity of the peptide for the stationary phase. In addition, near‐planar bandbroadening behaviour indicated that conformational species interconverted with rapid rate constants compared with the chromatographic time scale. These results indicated that the conformational change at 25°C in theRP‐HPLC system most likely corresponds to the unfolding of an α‐helical and/or β‐sheet structure to an extended coil structure. Therefore, the strong chemotactic properties of this peptide may be attributed to its ability to form considerable secondary structure in the presence of a hydrophobic environment. 相似文献
968.
Leonardo Furi Maria Laura Ciusa Daniel Knight Valeria Di Lorenzo Nadia Tocci Daniela Cirasola Lluis Aragones Joana Rosado Coelho Ana Teresa Freitas Emmanuela Marchi Laura Moce Pilar Visa John Blackman Northwood Carlo Viti Elisa Borghi Graziella Orefici the BIOHYPO Consortium Ian Morrissey Marco Rinaldo Oggioni 《Antimicrobial agents and chemotherapy》2013,57(8):3488-3497
The MICs and minimum bactericidal concentrations (MBCs) for the biocides benzalkonium chloride and chlorhexidine were determined against 1,602 clinical isolates of Staphylococcus aureus. Both compounds showed unimodal MIC and MBC distributions (2 and 4 or 8 mg/liter, respectively) with no apparent subpopulation with reduced susceptibility. To investigate further, all isolates were screened for qac genes, and 39 of these also had the promoter region of the NorA multidrug-resistant (MDR) efflux pump sequenced. The presence of qacA, qacB, qacC, and qacG genes increased the mode MIC, but not MBC, to benzalkonium chloride, while only qacA and qacB increased the chlorhexidine mode MIC. Isolates with a wild-type norA promoter or mutations in the norA promoter had similar biocide MIC distributions; notably, not all clinical isolates with norA mutations were resistant to fluoroquinolones. In vitro efflux mutants could be readily selected with ethidium bromide and acriflavine. Multiple passages were necessary to select mutants with biocides, but these mutants showed phenotypes comparable to those of mutants selected by dyes. All mutants showed changes in the promoter region of norA, but these were distinct from this region of the clinical isolates. Still, none of the in vitro mutants displayed fitness defects in a killing assay in Galleria mellonella larvae. In conclusion, our data provide an in-depth comparative overview on efflux in S. aureus mutants and clinical isolates, showing also that plasmid-encoded efflux pumps did not affect bactericidal activity of biocides. In addition, current in vitro tests appear not to be suitable for predicting levels of resistance that are clinically relevant. 相似文献
969.